OlsenJ.O., PozderacR.V., HinkleG.Somatostatin imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan). Semin Nucl Med.1995; 25: 251–261.
3.
GoldenbergD.M., DeLandF.H., KimE.E.Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med.1978; 298: 1384–1388.
4.
LarsonS.M.Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. Radiology.1987; 165: 297–304.
MassugerLFAG, ClaessensRAMJ, KenemanP.Kinetics and biodistribution in relation to tumour detection with 111In-labelled OC-TL 3 F(ab’)2 in patients with ovarian cancer. Nucl Med Commun.1991; 12: 593–609.
7.
OttR.J., GreyL.I., ZivanovicM.A.The limitations of the dual radionuclide subtraction technique for the external detection of tumours by radioiodine-labelled antibodies. Br J Radiol.1993; 56: 101–108.
8.
LoboguerreroA., PeraultC., LiehnJ.C.Volume rendering and bicolour scale in double isotope studies: application to immunoscintigraphy and bone landmarking. Eur J Nucl Med.1992; 19: 201–204.
9.
LiehnC-C, LoboguerreroA., PeraultC.Superimposition of computed tomography and single photon emission tomography immunoscintigraphic images in the pelvis: validation in patients with colorectal or ovarian carcinoma recurrence. Eur J Nucl Med.1992; 19: 186–194.
10.
RosenblumM.G., LamkiL.M., MurrayJ.L.Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst.1988; 80: 15–20.
11.
GhoshA.K., CernyT., WagstaffJ.Effect of in vivo administration of interferon gamma on expression of MHC products and tumor associated antigens in patients with metastatic melanoma. Eur J Cancer Clin Oncol.1989; 25: 1637–1643.
12.
GaspariniM., ZampinoM.G., MaffioliL.Enhancement of in vivo monoclonal antibody targeting with recombinant interferon and cytokines. Int J Biol Markers.1993; 8: 160–165.
13.
PaganelliG., MagnaniP., FazioF.Pretargeting of carcinomas with the avidin-biotin system. Int J Biol Markers.1993; 8: 155–159.
14.
ModoratiG., BrancatoR., PaganelliG.Immunoscintigraphy with three-step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br J Ophthalmol.1994; 78: 19–23.
15.
PaganelliG., BelloniC., MagnaniP.Two-step tumour targeting in ovarian cancer patients using biotinylated monoclonal antibodies and radioactive streptavidin. Eur J Nucl Med.1992; 19: 322–329.
16.
SomasundaramC., MatzkuS., SchuhmacherJ.Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy. Cancer Immunol Immunother.1993; 36: 337–345.
17.
SurwitE.A., ChildersJ.M., KragD.N.Clinical assessment of 111-In-cyt-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol.1993; 48: 285–292.
18.
GallupD.G.Multicenter clinical trial of 111-In-cyt-103 in patients with ovarian cancer. Targ Diagn Ther.1992; 6: 111–124.
19.
KimE.E., KasiL.P.Editorial: challenges in immunoscintigraphy of ovarian cancer. Gynecol Oncol.1993; 48: 283–284.
20.
QianH., FengJ., CuiH.Clinical evaluation of radioimmunoimaging with 133-I-coc183B2 monoclonal antibody against ovarian carcinoma by intraperitoneal injection. Gynecol Oncol.1992; 47: 216–222.
21.
ButlerJ., AttiyehF.F., DalyJ.M.Hepatic resection for metastasis of the colon and rectum. Surg Gynecol Obstet.1986; 162: 109–113.
22.
BallantyneG.H., QuinJ.Surgical treatment of liver metastases in patients with colorectal cancer. Cancer.1993; 71(suppl): 4252–4266.
23.
BaumR.P., LorenzM., HootenrottC.Immunoscintigraphy and continuous regional chemotherapy of liver metastases: a prospective study controlled by surgery, histology and immunohistochemistry. J Nucl Med.1987; 28: 35–42.
24.
TurkP.S., WaneboH.J.Results of surgical treatment of nonhepatic recurrence of colorectal carcinoma. Cancer.1993; 71(suppl): 4267–4277.
25.
DoerrR.J., HerreraL., Abdel-NabiH.In-111 CYT-103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer. Cancer.1993; 71(suppl): 4241–4247.
26.
CollierB.D., Abdel-NabiH., DoerrR.J.Immunoscintigraphy performed with In-111 labeled CYT-103 in the management of colorectal cancer: comparison with computed tomography. Radiology.1992; 185: 179–186.
27.
DoerrR.J., Abdel-NabiH., KragD.Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg.1991; 214: 118–124.
28.
NealC.E., MeisL.C.Correlative imaging with monoclonal antibodies in colorectal, ovarian and prostate cancer. Semin Nucl Med.1994; 24: 272–285.
29.
TemperoM.Pitfalls in antibody imaging in colorectal cancer. Cancer.1993; 7(suppl): 4248–4251.
30.
Abdel-NabiH.H., ChanH.W., DoerrR.J.Indium-labeled anticolorectal carcinoma monoclonal antibody accumulation in non-tumor tissue in patients with colorectal carcinoma. J Nucl Med.1990; 31: 1975–1979.
31.
DoerrR.J., Abdel-NabiH., KragD.Radiolabeled antibody imaging in the management of colorectal cancer. Ann Surg.1991; 214: 118–124.
32.
Abdel-NabiH.H., DoerrR.J., ChanH.W.Safety and role of repeated administrations of indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE 025 in the postoperative follow-up of colorectal carcinoma patients. J Nucl Med.1992; 33: 14–22.
33.
RyanJ.W.Immunoscintigraphy in primary colorectal cancer. Cancer.1993; 71(suppl): 4217–4224.
ReubiJ.C., KvolsL., KrenningE.P.Distribution of somatostatin receptors in normal and tumor tissue. Metabolism.1990; 39: 78.
38.
ReubiJ.C., Krenning, LambertsS.W.In vitro detection of somatostatin receptors in human tumors. Digestion.1993; 54(suppl 1): 76–83.
39.
BarrieR., WolteringE.A., HajarizahehH.Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res.1993; 55: 446.
MozellE., StenzelP., WolteringE.A.Functional endocrine tumors of the pancreas: clinical presentation, diagnosis and treatment. Curr Probl Surg.1990; 27: 303.
42.
MelmedS.Octreotide stimulates insulin-like growth factor binding-protein-I: a novel mechanism of drug action on acromegaly. Semin Oncol.1994; 21(suppl): 65.
43.
OlsenJ.O., PozderacR.V., HinkleG.Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (OctreoScan). Semin Nucl Med.1995; 25: 251–261.
DorrU., RathU., Sautter-BihlM.L.Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med.1993; 20: 431.
46.
WolteringE.A., O'DorisioM.S., O'DorisioT.M.The role of radiolabeled somatostatin analogs in the management of cancer patients. In: DeVitaV.T.Jr, HellmanS., RosenbergS.A., eds. Principles and Practice of Oncology.Philadelphia, Pa: Lippincott-Raven; 1995: 1–16.
47.
KrenningE.P., KwekkeboomD.J., BakkerW.H.Somatostatin receptor scintigraphy with (111-In-DTPA-D-Phe) and (1231-Tyr3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med.1993; 20: 716–731.
48.
KingC.M.P., RezhekR.H., BomanjiJ.Imaging neuroendocrine tumors with radiolabeled somatostatin analogues and x-ray computed tomography: a comparative study. Clin Radiol.1993; 48: 386–397.
49.
O'ByrneK.J., EnnisJ.T., FreyneP.J.Scintigraphic imaging of small cell lung cancer with 111-In pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer.1994; 69: 762.
50.
BongS.B., VanderJ.G., LaanH.Clinical experience with somatostatin receptor imaging in lymphoma. Semin Oncol.1994; 21(suppl 13): 46.
51.
KoperJ.W., ReubiJ.C., KrenningE.P.Endocrine aspects of diagnosis and treatment of primary brain tumors. Clin Endocrinol.1992; 35: 1.
52.
LuykenC., HildebrandtG., ScheidhauerK.111-In (DPTA-octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir (Wein).1994; 127: 60.
53.
van EijckC.H.J., KrenningE.P., BootsmaA.Somatostatin receptor scintigraphy in primary breast cancer. Lancet.1994; 343: 640.
54.
BarberH.B., BarrettH.H., WoolfendenJ.M.Comparison of in vivo scintillation probes and gamma cameras for detection of small, deep tumors. Phys Med Biol.1989; 34: 727–739.
55.
WoolfendenJ.M., BarberH.B.Radiation detector probes for tumor localization using tumor-seeking radioactive tracers. AJR Am J Roentgenol.1989; 153: 35–39.
56.
TuttleS.E., JewellS.D., MojzisikC.M.Intraoperative radioimmunolocalization of colorectal carcinoma with a hand-held gamma probe and Mab B72.3: comparison of in vivo gamma probe counts with in vitro Mab radiolocalization. Int J Cancer.1988; 42: 352–358.
57.
SardiS., WorkmanM., MojzisikC.Intraabdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system). Arch Surg.1989; 124: 55–59.
58.
CohenA.M., MartinE.W., LaveryI.Radioimmunoguided surgery using iodine-125 B72.3 in patients with colorectal cancer. Arch Surg.1991; 126: 349–352.
59.
FeistelH., WolfF., JagerW.Resection guided by antibodies (iodinized)-REGAI: Eine neue chirurgische Möglilchkeit zur Lokalisierung von kleinsten Ovarialkarzinom im Anschluss an Immunszintigraphie. In: HoferR., BergmannH., eds. Radioaktiv Isotope in Klinik und Forschung.Stuttgart: Schattlauer; 1988: 63–69.
60.
BadalamentR.A., BurgersJ.K., PettyL.R.Radioimmunoguided radical prostatectomy and lymphadenectomy. Cancer.1993; 71: 2268–2275.
61.
WolteringE.A., BarrieR., O'DorosioT.M.Detection of occult gastrinomas with 125-iodine labeled lanreotide and intraoperative gamma detection. Surgery.1994; 116: 1139.
62.
SchirmerW.J., O'DorisioT.M., SchirmerT.P.Intraoperative localization of neuroendocrine tumors with 125-I-tyr(3)-octreotide and a hand-held gamma-detecting probe. Surgery.1993; 114: 745.
63.
MortonD.L., WenD.R., WongJ.H.Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg.1992; 127: 392–399.
64.
BermanC., NormanJ., CruseC.W.Lymphoscintigraphy in malignant melanoma. Ann Plast Surg.1992; 28: 29–32.
65.
UrenR.F., Howman-GilesR.B., ThompsonJ.F.Mammary lymphoscintigraphy in breast cancer. J Nucl Med.1995; 36: 1775–1780.
66.
AlazrakiN.Editorial: lymphoscintigraphy and the intraoperative gamma probe. J Nucl Med.1995; 36: 1780–1783.
67.
WolfA.P., FowlerJ.S.Positron emission tomography: biomedical research and clinical application. Neuroim Clin North Am.1995; 5: 87–101.
68.
WarburgO.On the origin of cancer cells. Science.1956; 123: 309–314.
69.
FlierJ.S., MuecklerM.M., UsherP.Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science.1987; 235: 1492–1495.
70.
WeberG.Enzymology of cancer cells. N Engl J Med.1977; 296: 486–493.
71.
HawkinsR.A., ChoiY., HuangS.C.Editorial: quantitating tumor glucose metabolism with FDG and PET. J Nucl Med.1992; 33: 339–344.
72.
ColemanR.E., HoffmanJ.M., HansonM.W.Clinical application of PET for the evaluation of brain tumors. J Nucl Med.1991; 32: 616–622.
73.
Di ChiroG.Positron emission tomography using 18FDG in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol.1986; 22: 360–371.
74.
AlaviJ.B., AlaviA., ChawlukJ.Positron emission tomography in patients with glioma: a predictor of prognosis. Cancer.1988; 62: 1074–1078.
75.
FrankavillaT.L., MiletichR.S., Di ChiroG.Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. J Neurosurg.1989; 24: 1–5.
76.
Di ChiroG., OldfieldE., WrightD.C.Cerebral necrosis after radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR Am J Neuroradiol.1987; 8: 1083–1091.
77.
RosenfeldS.S., HoffmanJ.M., ColemanR.E.Studies of primary central nervous system lymphoma with 18F fluorodeoxyglucose positron emission tomography. J Nucl Med.1992; 33: 532–536.
78.
HoffmanJ.M., WaskinH.A., SchifterT.FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med.1993; 34: 567–575.
79.
GlantzM.J., HoffmanJ.M., ColemanR.E.Identification of early recurrence of primary central nervous system tumors by 18F fluorodeoxyglucose positron emission tomography. Ann Neurol.1991; 29: 347–355.
80.
LarsonS.M.Editorial: cancer of inflammation? A holy grail for nuclear medicine. J Nucl Med.1994; 35: 1653–1655.
81.
SasakiM., IchiyaY., KuwabaraY.Ringlike uptake of 18FDG in brain abscess: a PET study. J Comput Assist Tomogr.1990; 14: 486–487.
82.
GriffethL.K., RichK.M., DehdashtiF.Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology.1993; 186: 37–44.
MosskinM., EricsonK., HindmarshH.Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol.1989; 30: 225–232.
85.
Leskinen-KallioS.Positron emission tomography in oncology. Clin Physiol.1994; 14: 329–335.
86.
Von SchoberO., MeyerG.I., DudenD.Die Aufnahme von Aminosauren in Hirntumoren mit der Positronen-Emissionstomographie als Indikator fur die Beurtelung von Stoffwechselaktivitat und Malignitat. Fortschr Röntgenstr.1987; 147: 503–509.
87.
BergstromM., MuhrC., LundbergP.O.PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med.1991; 32: 610–615.
88.
HawkinsR.A., HohC., GlaspyJ.Positron emission tomography scanning in cancer. Cancer Invest.1994; 12: 74–87.
89.
JabourB.A., ChoiY., HohC.K.Extracranial head and neck PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology.1993; 186: 27–35.
90.
GoldbergM.A., LeeM.J., FischmanA.J.Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. RadioGraphics.1993; 13: 1047–1062.
91.
GallagherB.M., FowlerJ.S., GuttersonN.I.Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med.1978; 19: 1154–1161.
92.
ItoK., KatoT., TadokoroM.Recurrent rectal cancer and scar: differentiation with PET and MR imaging. Radiology.1992; 182: 549–552.
93.
CaseyM.J., GuptaN.C., MuthsC.K.Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol.1994; 53: 331–338.
94.
LapelaM., Leskinen-KallioS., VarpulaM.Imaging of uterine carcinoma by carbon-111-methionine and PET. J Nucl Med.1994; 35: 1618–1623.
95.
LapelaM., Leskinen-KallioS., VarpulaM.Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J Nucl Med.1995; 36: 2196–2200.
96.
ScottW.J., SchwabeJ.L., GuptaN.C.Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]-fluorodeoxyglucose. Ann Thorac Surg.1994; 58: 698–703.
97.
DobkinJ.A., MintonM.A.Editorial: clinical PET – Aesop's tortoise?Radiology.1993; 186: 13–15.
98.
BlasbergR.G.Prediction of brain tumor therapy response by PET. J Neuro-Oncol.1994; 22: 281–286.
99.
CoxP.H., BelferA.J., vander PompeW.B.Thallium-201 chloride uptake in tumors: a possible complication in heart scintigraphy. Br J Radiol.1976; 49: 767–768.
100.
WackersFJ-Th, BermanD.S., MaddahiJ.Technetium-99m-hexakis-2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med.1989; 30: 301–311.
101.
ElgazzarA.H., Fernandez-UlloaM., SelbersteinE.B.201-T1 as a tumour-localizing agent: current status and future considerations. Nucl Med Commun.1993; 14: 96–103.
102.
AndoA., AndoI., KatayamaM.Biodistribution of T1–201 in tumor bearing animals and inflammatory lesions in induced animals. Eur J Nucl Med.1987; 12: 567–572.
103.
KaplanW.D., TakvorianT., MorrisJ.H.Thallium-201 brain tumor imaging: a comparative study with pathologic correlation. J Nucl Med.1987; 28: 47–52.
104.
MochizukiT., TakechiT., MurascK.Subtraction for liver tumor imaging using thallium-201, technetium-99m colloid and three head SPECT. J Nucl Med.1993; 34S: 985. Abstract.
105.
BlackK.L., HawkinsR.A., KimK.T.Use of thallium-201 SPECT to quantitate malignancy grade of gliomas. J Neurosurg.1989; 71: 342–346.
106.
CarvalhoP.A., SchwartzR.B., AlexanderE.Detection of recurrent gliomas with quantitative thallium-201/technetium-99m HMPAO single-photon emission computerized tomography. J Neurosurg.1992; 77: 565–570.
107.
SchwartzR.B., CarvalhoP.A., AlexanderE.Radiation necrosis vs high-grade recurrent glioma: differentiation by using dual-isotope spect with 201T1 and 99mTc-HMPAO. AJNRAm J Neuroradiol.1992; 12: 1187–1192.
108.
BartoliniA., GasparettoB., AlbanoC.Assessment of 99m-Tc-HM-PAO parameters with SPECT for improved evaluation of blood flow in cerebral lesions. Comput Med Imaging Graphics.1991; 15: 303–309.
109.
RamannaL., WaxmanA., BraunsteinG.T1–201 scintigraphy in differentiated thyroid cancer: comparison with radiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med.1991; 32: 441–446.
110.
MullerS.P., Guth-TougelidisB., PiotrowskiB.T1–201 scintigraphy in the follow-up of eosinophilic thyroid carcinoma. J Nucl Med.1991; 31: 407.
111.
RamannaL., WaxmanA.D., BinneyG.Th-201 scintigraphy in bone sarcoma: comparison with Fa-67 and Tc-99m MDP in the evaluation of chemotherapeutic studies. J Nucl Med.1990; 31: 567–571.
112.
NishizawaK., OkunieffP., ElmalehD.Blood flow of human soft tissue sarcomas measured by T1–201 scanning: prediction of tumor response to radiation. J Nucl Med.1990; 31: 567–571.
113.
ElgazzarA.H., Abdel-DayemH.M., HalkerR.Experience with thallium-201 imaging in head and neck cancer. Clin Nucl Med.1988; 13: 286–289.
114.
LeeV.W., RosenM.P., BaumA.AIDS-related Kaposi's sarcoma: findings on thallium-201 scintigraphy. Am J Radiol.1988; 151: 1233–1235.
115.
TonamiN., YokoyamaK., ShukeN.Evaluation of suspected malignant pulmonary lesions with 201-T1 single-photon emission computed tomography. Nucl Med Commun.1993; 14: 602–610.
116.
CarvalhoP.A., ChiuM.L., KronaugeJ.F.Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med.1992; 33: 1516–1521.
117.
SinusasA.J., TrautmanK.A., BerginJ.D.Quantification of area of risk during coronary occlusion and degree of myocardial salvage after reperfusion with Tc-99m 2-methosyisobutylisonitrile. Circulation.1990; 82: 1424–1437.
118.
Piwnica-WormsD., ChiuM.L., KronaugeJ.F.Enhancement of Tc-99m SestaMIBI accumulation multidrug resistance (MDR) cells by cytotoxic drugs and MDR reversing agents. J Nucl Med.1993; 34: 140P. Abstract.
119.
MaublantJ.C., ZhangZ., RappM.In vitro uptake of technetium-99m-teboroxime in carcinoma cell lines and normal cells: comparison with technetium-99m-sestamibi and thallium-201. J Nucl Med.1993; 34: 1949–1952.
PodoloffD.A.The role of radionuclide scans in sarcoma. Hematol Oncol Clin North Am.1995; 9: 605–626.
122.
FreitasJ.E., FreitasA.E.Thyroid and parathyroid imaging. Semin Nucl Med.1994; 24: 234–245.
123.
TailleferR., RobidouxA., LambertR.Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med.1995; 36: 1758–1765.
124.
KhalkhaliI., CutroneJ., MenaI.Technetium-99m-sestamibi scintimammography of breast lesions: clinical and pathological follow-up. J Nucl Med.1995; 36: 1784–1789.
